Kwetaplex

Quetiapine, the active ingredient in Kwetaplex, is an atypical antipsychotic presented as an oral tablet for oral use. It treats schizophrenia, bipolar disorder, and is used as adjunctive therapy for major depressive disorder in adults.

GNH USA supplies Kwetaplex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kwetaplex, an atypical antipsychotic, acts on dopamine and serotonin pathways to manage serious mental health conditions. - Schizophrenia: reduces psychotic symptoms such as hallucinations and delusions. - Bipolar disorder: stabilises mood and diminishes manic episodes. - Major depressive disorder (adjunctive): enhances the effect of primary antidepressants in treatment‑resistant cases.

Common Side Effects: - Sedation or drowsiness - Dizziness or light‑headedness - Dry mouth - Constipation - Weight gain - Orthostatic hypotension

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Agranulocytosis or severe neutropenia - Marked hypotension or cardiovascular collapse - Seizures - Suicidal thoughts or behaviours - Cardiac arrhythmias, including QT prolongation

Before initiating therapy, consider the following precautions: - Pregnancy: Category B – use only if potential benefit outweighs risk. - Hepatic impairment: dose may need adjustment in moderate to severe liver disease. - Elderly patients: increased sensitivity to sedation and falls; start at low dose. - Concomitant CNS depressants: may enhance drowsiness and impair coordination. - Metabolic monitoring: regularly assess weight, glucose, and lipid levels. - Store at ambient temperature: keep below 25 °C, protect from moisture and keep in original packaging.

Quetiapine may interact with several drug classes; monitoring is essential. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may raise quetiapine levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce efficacy. - Other antipsychotics – additive risk of QT prolongation and extrapyramidal symptoms.

Moderate Interactions (Monitor Closely): - CNS depressants (alcohol, benzodiazepines) – increased sedation. - Antihypertensives – enhanced orthostatic hypotension. - Anticholinergic agents – heightened anticholinergic burden. - Certain antidepressants (SSRIs, SNRIs) – potential pharmacokinetic changes. - Smoking – may induce metabolic enzymes affecting plasma concentrations.